Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 5/20 | 0.46 |
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374909 | 0.85 | ALDH1A1 (0.66) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL6089740 | 0.82 | ESR1 (0.51) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL15156887 | 0.82 | NPC1 (0.48) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL340143 | 0.82 | NPC1 (0.55) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL56223 | 0.82 | ALDH1A1 (0.61) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL29397448 | 0.79 | ESR1 (0.56) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL565076 | 0.79 | ESR1 (0.56) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL29412591 | 0.79 | ESR1 (0.56) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL1024107 | 0.79 | MAPT (0.69) | ESR1ESR2ARMAPTMEN1 | |
| SCHEMBL9353505 | 0.78 | MAPT (0.46) | ESR1ESR2ARCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190899-A1 | HARDENABLE EPOXY RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2010-07-29 | — | — | US | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-10-15 | — | — | US | disclosed |
| EP-1933834-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| WO-2007042816-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| US-7109376-B2 | Benzene and naphthylene derivatives and their use as UV screening agents | DSM IP ASSETS B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| US-20060153784-A1 | Novel 2-benzoxazolyl benzene derivatives and their use as UV screening agents | HUBER ULRICH | 2006-07-13 | — | — | US | disclosed |
| US-7019020-B2 | 2-benzoxazolyl benzene derivatives and their use as UV screening agents | DSM IP ASSETS B.V. (NL) | 2006-03-28 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| CN-1531530-A | Novel 2-benzoxazolyl benzene derivatives and their use as UV screening agents | 罗奇维生素股份公司 | 2004-09-22 | — | — | CN | disclosed |
| US-20040071640-A1 | Novel-2-benzoxazolyl benzene derivatives and their use as uv screening agents | DSM IP ASSETS B.V. (NL) | 2004-04-15 | — | — | US | disclosed |
| EP-1358167-A1 | NOVEL 2-BENZOXAZOLYL BENZENE DERIVATIVES AND THEIR USE AS UV SCREENING AGENTS | Roche Vitamins AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002062771-A1 | NOVEL 2-BENZOXAZOLYL BENZENE DERIVATIVES AND THEIR USE AS UV SCREENING AGENTS | ROCHE VITAMINS AG (CH) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | ESR1 2639/4885ESR2 1863/4885AR 2064/4885 |
| US-20040071640-A1 | Novel-2-benzoxazolyl benzene derivatives and their use as uv screening agents | CBX8, XRCC5, CYP8B1 | ESR1 2558/4885ESR2 876/4885AR 471/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | ESR1 211/4885ESR2 161/4885AR 79/4885 |
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | ESR1 2346/4885ESR2 1817/4885AR 4228/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | ESR1 273/4885ESR2 191/4885AR 86/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | ESR1 204/4885ESR2 166/4885AR 78/4885 |
| US-20060153784-A1 | Novel 2-benzoxazolyl benzene derivatives and their use as UV screening agents | POLR1C, CBR3, CBR1 | ESR1 337/4885ESR2 309/4885AR 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.